PLX
PLX clinical trials: Protalix BioTherapeutics, Inc.
Every trial on ClinicalTrials.gov where Protalix BioTherapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 17
- Trials linked
- 16
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PLX on the catalyst calendar · PLX registry changes
- Primary completion Dec 2027Sponsor estimatePhase 2NCT07280156A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and...Protalix · GoutRecruitingPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 26, 2024ActualPhase 1NCT05745727A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid LevelsProtalix · GoutCompletedPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2019ActualPhase 3NCT03018730Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)Protalix · Fabry DiseaseCompletedPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2020ActualPhase 3NCT03180840Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 WeeksProtalix · Fabry DiseaseCompletedPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2021ActualPhase 3NCT02795676Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal FunctionProtalix · Fabry DiseaseCompletedPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 26, 2020ActualPhase 1/Phase 2NCT01981720Extension Study of PRX-102 for up to 60 MonthsProtalix · Fabry DiseaseCompletedPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 6, 2016ActualPhase 1/Phase 2NCT01678898Dose-ranging Study of PRX-102 in Adult Fabry Disease PatientsProtalix · Fabry DiseaseCompletedPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2018Sponsor estimatePhase 3NCT02921620Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry DiseaseProtalix · Fabry DiseaseWithdrawnPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 2NCT02107846An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112Protalix · Gaucher DiseaseCompletedPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2017Sponsor estimatePhase 2NCT02768974Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative ColitisProtalix · Ulcerative ColitisUnknown statusPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2017Sponsor estimatePhase 2NCT02722122Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic...Protalix · Cystic FibrosisUnknown statusPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2016ActualPhase 1NCT02605590Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult VolunteersProtalix · Cystic Fibrosis (CF)CompletedPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualPhase 1NCT02107833Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy VolunteersProtalix · Human VolunteerCompletedPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2014ActualPhase 1NCT01747980Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease PatientsProtalix · Gaucher DiseaseCompletedPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2010ActualEarly Phase 1NCT01093859An Exploratory Phase 1 Microdose Study of PRX-105Protalix · Organophosphate ExposureCompletedPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 1NCT00258778Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)Protalix · Gaucher DiseaseCompletedPLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2022ActualNo phase registeredNCT05186324Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly InfusionChiesi Farmaceutici S.p.A. · Fabry DiseaseCompletedPLXCollaboratorIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 17 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner